Skip to content
PeptideAgent

Clinics in Tennessee

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What Tennessee law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and verified listings.

Tennessee at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified clinics serving Tennessee

No verified clinics serving Tennessee are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in Tennessee

Yes. A Tennessee resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Tennessee-licensed prescriber, including by telehealth under Tennessee Code section 63-1-155, and can obtain a compounded peptide when it is eligible under federal 503A rules and dispensed by a pharmacy licensed by the Tennessee Board of Pharmacy. Tennessee tightened compounding oversight after the 2012 fungal meningitis outbreak: section 63-10-216 requires out-of-state compounding pharmacies to submit a home-state inspection from the previous 12 months before licensure, and Board rule chapter 1140-07 sets sterile compounding standards that cover injectable peptides. [1] [2] [3] [4] [5] [6]

Compounded GLP-1 access in Tennessee

Tennessee has not adopted a looser rule, and because injectable GLP-1s are sterile preparations, a pharmacy compounding them for a Tennessee patient must also meet rule chapter 1140-07 and, if out of state, the section 63-10-216 inspection requirement. [4] [5] [7]

Research use only sellers in Tennessee

Under title 63, chapter 10, only licensed pharmacies may dispense prescription drugs to Tennessee patients, so a seller shipping "research use only" injectable peptides to Tennessee consumers is not operating under Board of Pharmacy licensure. [1] [8]

How to check a clinic in Tennessee

  1. Confirm the prescribing clinician's license with the Tennessee medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the Tennessee Board of Pharmacy (Tennessee Department of Health) license lookup. [1] [4] [5] [6]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Tennessee. [1] [8]

Common questions in Tennessee

Can I get a GLP-1 prescription in Tennessee through telehealth?

Yes. Section 63-1-155 lets a Tennessee-licensed provider establish a relationship and treat you by telehealth under the same standard of practice as an office visit. Before prescribing, the provider still has to take a history, perform an appropriate examination, make a diagnosis, and plan follow-up. [2] [3]

Can a Tennessee licensing board make telehealth rules stricter than in-person rules?

No. Section 63-1-155 bars the board governing a provider from setting a more restrictive standard of practice for telehealth than the provider's practice act allows. Telehealth care is held to the same standard as in-person care, not a lower or higher one. [2]

All peptide legal questions for Tennessee

Sources

  1. [1]Tennessee Board of Pharmacy (Tennessee Department of Health)
  2. [2]Tennessee Code section 63-1-155, Telehealth and telemedicine services, provider-patient relationship, standard of practice
  3. [3]Tennessee Board of Medical Examiners: Telemedicine FAQ
  4. [4]Tennessee Code section 63-10-216, Compounding pharmacies
  5. [5]Rules of the Tennessee Board of Pharmacy chapter 1140-07, sterile compounding standards
  6. [6]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  7. [7]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  8. [8]21 U.S.C. 331, Prohibited acts